Phase 1 Rheumatoid Arthritis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Your Body Mass Index (BMI) must be below 35 (a measure of body weight relative to height)
- You have been diagnosed with rheumatoid arthritis (RA) that started in adulthood and is considered moderate to severe
- Your RA is currently moderately to severely active
- You have tried and not responded well enough to at least 2 specific types of RA medications called b/tsDMARDs (confirm with trial site)
- You have 4 or more swollen joints at the time of screening
- There is evidence of joint inflammation shown through a physical exam and/or an ultrasound scan
- You have not responded well enough to, or could not tolerate, available RA treatments
- You have been on a stable dose of your current RA medications for at least 30 days
- You are using a highly effective form of birth control if applicable
Who may not be able to join:
- You have had major surgery in the last 12 weeks, or are planning to have major surgery within 12 months of receiving the trial treatment
- You have an uncontrolled serious condition affecting your heart, lungs, kidneys, liver, hormones, or digestive system
- You have frequent infections or currently have an active infection
- You have active tuberculosis (TB) or untreated latent (inactive/dormant) TB
- You have a condition that weakens your immune system, either from birth or developed later in life
- You have a history of, or currently have, any other inflammatory joint disease besides rheumatoid arthritis
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Sarah Baxter, MD, PhD, Sonoma Biotherapeutics, Inc.
Phone: 415-992-6245
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence, nature, and severity of adverse events [Safety and Tolerability]; Incidence and nature of dose-limiting toxicities (DLTs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.